Therapeutic effectiveness of conditioned medium derived from adipose tissue mesenchymal stem cells and dehydroepiandrosterone in a rat model of spinal cord injury.
Modarresi F., Kaka GR., Raei M., Rezaei-Tazangi F.
Animal Study on Spinal Cord Injury, published in IBRO Neurosci Rep (2026) — summary generated from the PubMed abstract.
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- IBRO Neurosci Rep (2026)
- Country
- Netherlands
- Reported sample size
- —
- PMID
- 41716730
- DOI
- 10.1016/j.ibneur.2025.12.010
Abstract (original English)
Spinal cord injury (SCI) is a severe neurological disorder that leads to significant complications, including loss of bladder/bowel control and increased infection risk. The current standard treatment involves methylprednisolone administration and surgical decompression, but finding an effective therapy with minimal side effects remains a major challenge. This study aimed to investigate the effects of an optimized conditioned medium derived from rat adipose-derived mesenchymal stem cells (AD-MSCs) and dihydroepiandrosterone (DHEA) on behavioral indices, oxidative stress, stereological parameters, and histopathological outcomes in rats with compressive spinal cord injury (SCI). In this study, 60 adult female rats were randomly divided into five groups: Sham group (laminectomy + intraperitoneal injection of 1 % dimethyl sulfoxide [DMSO], 200 µL for seven consecutive days), SCI-induced group (SCI induction + intraperitoneal injection of 1 % DMSO, 200 µL for seven consecutive days), Treatment group 1 (SCI induction + intraperitoneal injection of DHEA [30 mg/kg] dissolved in 1 % DMSO for seven consecutive days), Treatment group 2 (SCI induction + intraperitoneal injection of conditioned medium [200 µL] for seven consecutive days), Treatment group 3 (SCI induction + intraperitoneal injection of DHEA [30 mg/kg] dissolved in 1 % DMSO followed by conditioned medium [200 µL] for seven co
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence comes from animal or laboratory studies and has not been confirmed in humans.
How we grade evidenceRelated research
- Level ASystematic Review
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level ASystematic Review
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Systematic Review on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol - Level ASystematic Review
Brain-derived neurotrophic factor (BDNF) as biomarker in stem cell-based therapies of preclinical spinal cord injury models: A systematic review.
Systematic Review on Spinal Cord Injury, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
- 2025
Tissue Cell - Level ASystematic Review
Stem cell-derived exosomes for traumatic spinal cord injury: a systematic review and network meta-analysis based on a rat model.
Systematic Review on Spinal Cord Injury, published in Cytotherapy (2024) — summary generated from the PubMed abstract.
- 2024
Cytotherapy - Level ASystematic Review
Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury in Rat Models: A Systematic Review and Network Meta-Analysis.
Systematic Review on Spinal Cord Injury, published in Cell Transplant (2024) — summary generated from the PubMed abstract.
- 2024
Cell Transplant - Level ASystematic Review
Mesenchymal stem cell-derived extracellular vesicles therapy in traumatic central nervous system diseases: a systematic review and meta-analysis.
Systematic Review with a reported sample of 52 on Spinal Cord Injury, published in Neural Regen Res (2023) — summary generated from the PubMed abstract.
- 2023
- n = 52
Neural Regen Res